Tirzepatide Evidence Guide
Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude.
Our Take
Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude.
- Best for
- Obesity, type 2 diabetes, obstructive sleep apnea with obesity, metabolic syndrome research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 2.5mg subcutaneous weekly, titrating to 15mg over 20 weeks
Benefits and Evidence
- Weight Loss: Level A, includes human evidence - SURMOUNT-1 showed up to 22.5% weight loss at the highest dose. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity without diabetes and found -20.2% vs -13.7% mean weight change at 72 weeks, confirming superior weight loss versus semaglutide 2.4mg.
- Blood Sugar Control: Level A, includes human evidence - SURPASS trials demonstrated HbA1c reductions of up to 2.4%. Superior to semaglutide 1mg in SURPASS-2 head-to-head trial.
- Cardiovascular Risk Reduction: Level B, includes human evidence - Preliminary data suggests cardiovascular benefits, but semaglutide still has the more mature dedicated cardiovascular outcomes evidence in obesity via SELECT. SURPASS-CVOT and related tirzepatide outcomes data remain central to the evidence update path.
- Obstructive Sleep Apnea: Level A, includes human evidence - SURMOUNT-OSA supported FDA approval for moderate-to-severe OSA in adults with obesity. Two 52-week randomized trials showed clinically meaningful apnea-hypopnea index reductions versus placebo, likely mediated largely by weight loss.
- GI Side Effects: Level A, includes human evidence - Similar GI side effect profile to GLP-1 agonists. Nausea and diarrhea common during dose escalation but generally improve over time.
Side Effects and Warnings
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia
- Abdominal pain
- Injection site reactions
Research Dosage References
- <strong>Subcutaneous injection (diabetes)</strong> - 2.5-15 mg - Once weekly - Start at 2.5mg for 4 weeks, then increase. Target 5mg, 10mg, or 15mg (Mounjaro).
- <strong>Subcutaneous injection (weight)</strong> - 2.5-15 mg - Once weekly - Gradual escalation over 20 weeks to maximum tolerated dose (Zepbound).
Mechanism of Action
Tirzepatide has a dual mechanism of action: 1. GLP-1 receptor agonism: Similar to semaglutide, activates GLP-1 receptors to reduce appetite, stimulate insulin, and slow gastric emptying. 2. GIP receptor agonism: Additionally activates GIP receptors, which enhances insulin sensitivity in adipose tissue and may improve fat metabolism. 3. Synergistic effects: The combination of GIP and GLP-1 receptor activation produces greater metabolic benefits than either alone. 4. Beta cell protection: May improve pancreatic beta cell function and survival. 5. Lipid metabolism: Improves lipid profiles through enhanced fat oxidation and reduced lipogenesis.
Legal Status
FDA-approved for type 2 diabetes (Mounjaro, 2022), chronic weight management (Zepbound, 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 20, 2024). Prescription required. Availability may be limited due to high demand.
Primary Sources
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med, 2021.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med, 2025.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med, 2024.